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Abstract
Long-term potentiation (LTP), a long-lasting enhancement in communication between neurons, is considered to be the major
cellular mechanism underlying learning and memory. LTP triggers high-frequency calcium pulses that result in the activation
of Calcium/Calmodulin (CaM)-dependent kinase II (CaMKII). CaMKII acts as a molecular switch because it remains active for a
long time after the return to basal calcium levels, which is a unique property required for CaMKII function. Here we describe
the crystal structure of the human CaMKIId/Ca
2+/CaM complex, structures of all four human CaMKII catalytic domains in their
autoinhibited states, as well as structures of human CaMKII oligomerization domains in their tetradecameric and physiological
dodecameric states. All four autoinhibited human CaMKIIs were monomeric in the determined crystal structures but
associated weakly in solution. In the CaMKIId/Ca
2+/CaM complex, the inhibitory region adopted an extended conformation
and interacted with an adjacent catalytic domain positioning T287 into the active site of the interacting protomer.
Comparisons with autoinhibited CaMKII structures showed that binding of calmodulin leads to the rearrangement of residues
in the active site to a conformation suitable for ATP binding and to the closure of the binding groove for the autoinhibitory
helixbyhelixaD.Thestructuraldata,together withbiophysicalinteractionstudies, revealsthemechanismof CaMKII activation
by calmodulin and explains many of the unique regulatory properties of these two essential signaling molecules.
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Introduction
Calcium/Calmodulin (Ca
2+/CaM)-dependent serine/threonine
kinases (CaMKs) constitute a family of 81 proteins in the human
proteome that play a central role in cellular signaling by
transmitting Ca
2+ signals [1]. Kinases in this protein family are
activated through binding of Ca
2+/CaM to regulatory regions that
either flank the catalytic domain or are located in regulatory
molecules [2]. Four CaMKII isozymes (a, b, c, and d), in addition
to about 30 splice variants, are expressed in humans. The a and b
isoforms are brain specific and together make up approximately
1% of total brain protein in rodents and up to 2% of total protein
in their hippocampus [3]. The c and d isoforms are expressed in
most tissues, but in comparison have much lower expression levels
[4,5]. The unique switch-like properties of CaMKII activation and
its extremely high abundance in the brain identified CaMKII as a
key regulator of cellular memory and learning [6]. CaMKII is
essential for the induction of long-term potentiation (LTP), a long-
lasting increase in the efficiency of synaptic transmission between
neurons that is believed to be a cellular correlate of memory [7,8].
Stimuli that induce LTP lead to autophosphorylation at T286 in
CaMKIIa (T287 in the b, c, and d isoforms), thereby resulting in
sustained CaMKII activation [9]; mice expressing the CaMKIIa
T286A mutant were severely impaired in learning [10].
Several CaMKIId variants are highly abundant in myocardial
tissue [11,12]. Increased CaMKII activity has been observed in
patients with structural heart disease and arrhythmias, where
prolonged action potential duration leads to sustained hyperacti-
vation of CaMKII and heart failure [11].
CaMKII proteins form large oligomeric structures. The N-
terminal kinase domain is tethered via an autoinhibitory helix and a
calmodulin binding site to a C-terminal oligomerization domainthat
PLoS Biology | www.plosbiology.org 1 July 2010 | Volume 8 | Issue 7 | e1000426organizes the enzyme into ring-shaped oligomers. Three-dimen-
sional reconstruction of single-particle electron microscopy images
revealed dodecameric assemblies for all purified homogeneous full-
length CaMKII isozymes [13,14]. In contrast, tetradecamers were
detectedinthecrystalstructuresofisolatedoligomerization domains.
This non-physiological oligomerization state has been attributed to
the absence of the kinase domain [15,16].
The cellular regulation of CaMKII activity is the outcome of a
complex interplay between protein localization, heterooligomeriza-
tion, local Ca
2+/CaM concentrations, CaMKII autophosphoryla-
tion, and dephosphorylation of CaMKII by phosphatases [2,17].
The structure of the isolated Caenorhabditis elegans CaMKII
(CeCaMKII) kinase domain in its autoinhibited state provided the
first insight into the molecular mechanism of CaMKII regulation
[18]. In this structure the inhibitory domain forms a helix that binds
tightly to the substrate binding pocket preventing access of
substrates. Interestingly, the regulatory domains of two catalytic
domains interacted as antiparallel coiled-coils in the CeCaMKII
structure suggesting that the inhibitory helix mediates self
association in the inactive state of the enzyme. This association
model has also been evoked to explain cooperativity of CaMKII
activation by Ca
2+/CaM observed in enzyme kinetic assays and
‘‘pairing’’ of kinase domains in autoinhibited holoenzymes [19,20].
In the inactive state the autophosphorylation site within the
regulatory domains is not accessible [18]. It has been speculated
that this inhibitory ‘‘block’’ of the regulatory domain is released by
structural changes induced upon Ca
2+/CaM binding. Once
phosphorylated at the regulatory T286 site (CaMKIIa numbering)
by catalytic domains present in the same holoenzyme, steric
constraints prevent rebinding of the autoinhibitory domain to the
catalytic domain [4,21,22].
In addition, CaMKII can be made insensitive to Ca
2+/CaM by
autophosphorylation at T305/T306 located within the Ca
2+/CaM
binding site [23,24], a process that is facilitated by interaction
with the membrane associated guanylate kinase (MAGUK/CASK)
[25,26]. The balance between the Ca
2+/CaM-sensitive and
-insensitive CaMKII pool is critical for the regulation of post-
synaptic plasticity [27,28].
In CaMKIIa, autophosphorylation of T306 but not of T305 was
observed in vitro, leading to a strong reduction of Ca
2+/CaM binding
[29]. The region flanking this autophosphorylation site represents a
non-consensussubstratesiteforCaMKII,whichraisesthequestionof
how this motif would be efficiently recognized as a substrate.
To date, our structural knowledge of how CaMKIIs are activated
is based solely on structures of isolated kinase domains and peptide
complexes of either catalytic domains with their substrates or Ca
2+/
CaM with calmodulin binding sites [18,20]. We were interested in
describing the molecular mechanisms that govern CaMKII
activation in an intact catalytic domain/Ca
2+/CaM complex. The
structure of the CaMKIId/Ca
2+/CaM presented here captures
the kinase in a state where the inhibitory helix is dislodged from
the substrate binding site, thereby making it available for
autophosphorylation by an adjacent kinase molecule. Analysis of
this co-crystal structure, structures of all human isozymes in their
autoinhibited state, and in-solution association studies showed that
binding of Ca
2+/CaM triggers large structural changes in the kinase
domain as well as in the CaMKII regulatory domain that together
lead to allosteric kinase activation. Furthermore, we also describe
the structure of an oligomerization domain in its physiological,
dodecameric state. Based on the comparison of this large body of
structuralinformationand biochemicalcharacterizationwepropose
a model that explains the substrate recognition leading to Ca
2+/
CaM-dependent allosteric activation of human CaMKIIs.
Results
Structures of Autoinhibited Human CaMKII Isozymes
To date, our understanding of the molecular mechanisms that
define the CaMKII autoinhibited state are based on the structural
model of the C. elegans CaMKII orthologue (CeCaMKII). This
crystal structure shows an occluded substrate binding site,
rearrangements in the ATP binding site that disturb co-factor
binding and a remarkable dimeric assembly involving the
inhibitory helix and the CaM binding motif (corresponding to
residues K293-F313 in CaMKIIa) [18]. CeCaMKII and human
CaMKIIa share 77% sequence identity. We were interested in
determining whether regulatory mechanisms suggested based on
the crystal structure of CeCaMKII would be conserved in human
CaMKII isozymes. To address this, we determined the structures
of all human CaMKII isozymes in their autoinhibited state. The
structures were refined at resolutions ranging from 2.25 A ˚
(CaMKIIc) to 2.4 A ˚ (CaMKIIb). Details of the diffraction data
statistics and refinement have been summarized in Table S1.
Importantly, whereas the crystallized constructs of the a and b
isozymes contained the catalytic domain and the inhibitory region
but only a part of the Ca
2+/CaM binding motif, the constructs of
both CaMKIIc and CaMKIId additionally contained the entire
regulatory region as well as a part of the unstructured linker to the
association domain. The boundaries used for the crystallized
proteins are shown in the boxed sequence inserts in Figure 1A and
are indicated in the sequence alignment in Figure S1. As expected,
based on the high sequence homology, all structures exhibited a
high degree of structural similarity. The activation segments were
all well-ordered and helix aC was correctly positioned for catalysis
as indicated by formation of the conserved salt bridge between
E60 located in aC and lysine K41, which is a hallmark of the
active kinase conformation [30] (Figure S2).
Similar to the C. elegans orthologue, the substrate binding site is
blockedbytheregulatorydomaininallhumanCaMKIIs(Figure1B).
However, dimeric association as in CeCaMKII, i.e., mediated by the
Author Summary
CaMKII enzymes transmit calcium ion (Ca
2+) signals released
inside the cell by regulating signal transduction pathways
through phosphorylation: Ca
2+ first binds to the small
regulatory protein CaM; this Ca
2+/CaM complex then binds
to and activates the kinase, which phosphorylates other
proteins in the cell. Since CaMKs remain active long after
rapid Ca
2+ pulses have dropped they function as molecular
switches that turn on or off crucial cell functions in response
to Ca
2+ levels. The multifunctional CaMKII forms of this
enzyme – of which there are four in human – are important
in many processes including signaling in neurons and
controlling of the heart rate. They are particularly abundant
in the brain where they probably play a role in memory.
CaMKII forms an exceptionally large, dodecameric complex.
Here, we describe the crystal structure of this complex for
each of the four human CaMKII catalytic domains in their
autoinhibited states, a complex of CaMKII with Ca
2+/CaM, as
well asthestructureoftheoligomerizationdomain (thepart
of the protein that mediates complex formation) in its
physiological dodecameric state and in a tetradecameric
state. Detailed comparison of this large body of structural
data together with biophysical studies has allowed us to
better understand the structural mechanisms of CaMKII
activation by CaM and to explain many of the complex
regulatory features of these essential enzymes.
Structural Mechanism of CaMKII Activation
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human isozymes. As mentioned above, the C termini of the
crystallized c and d isozymes extended well beyond the Ca
2+/CaM
binding site (in CaMKIId, including the linker region up to S333).
However, the autoinhibitory helices in all isozymes were structured
only up to residue 302. Different crystal forms were observed,
containing one (CaMKIIc), two (CaMKIIa and CaMKIId), or four
molecules (CaMKIIb) in the asymmetric unit. However, no
indication of a conserved dimer interface was evident within the
crystals with packing contact regions typically involving small and
diverse surface areas. However, evidence that dimerization occurs in
solution was found using analytical ultracentrifugation (AUC)
sedimentation velocity experiments for all CaMKII catalytic domains
(exemplified by CaMKIId in Figure 1C), thus supporting studies that
identified inactive CaMKII as paired (dimers) in cells [19]. The
affinities, as estimated from the proportions between the areas of the
peaks for monomeric and dimeric species, were weak (KD of 200–
600 mM), but due to the high effective concentrations of catalytic
domains in the context of the holoenzyme, the observed interactions
are likely to be biologically relevant (Table S2). Similar association
constants were observed for all human CaMKIIs independent of the
construct length, suggesting that dimerization is not mediated by the
regulatory domain in human CaMKIIs. To test this hypothesis, we
repeated the AUC experiments in the presence of an isolated
regulatory domain peptide that spans the autoinhibitory region as
well as the Ca
2+/CaM binding site (CaMKIId residues 282–310).
Figure 1. Structural features of CaMKII and dimerization of the kinase domain. A) Domain organization of CaMKII. The catalytic, regulatory
and association domains are labelled, and predicted unstructured regions are shown in red. Sites of regulatory phosphorylation and oxidation are
indicated. N- and C-terminal boundaries of the crystallized catalytic domain constructs are highlighted by boxed-in residues within the insets. TheC -
terminal boundary of CaMKIId, which is C-terminal to the range depicted (S333) has not been included in the figure. The organization of the
autoinhibitory and the Ca
2+/CaM binding domain is shown in the boxed alignment below the cartoon. For comparison, the sequence of the C.
elegans (Ce) orthologue has also been included in the alignment. Secondary structural elements observed in the autoinhibited CaMKIId, CaMKIId/
Ca
2+/CaM, and C. elegans structure are shown above the alignment. The regions encompassing the Ca
2+/CaM binding and autoinhibitory domains are
highlighted in blue and green, respectively, and the phosphorylation sites are highlighted in yellow. B) Structural overview of the autoinhibited
CaMKIId kinase domain refined at 2.3 A ˚ resolution. The inhibitor bound at the ATP site is shown in surface representation in light-green, the activation
segment is highlighted in magenta and main secondary structural elements are labelled. C) AUC sedimentation velocity experiment showing self-
association of CaMKIId in absence (black line) and presence (red line) of a substrate-competitive peptide. The shift in sedimentation coefficient upon
peptide binding is indicated by an arrow.
doi:10.1371/journal.pbio.1000426.g001
Structural Mechanism of CaMKII Activation
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observed (red trace in Figure 1C), suggesting that binding of the
peptide did not interfere with dimerization in human CaMKIIs.
Binding of the peptide led to a significant shift towards smaller
sedimentation coefficients, suggesting that interaction with the
peptide induces a conformational change that leads to increased
friction. Based on these data, it is tempting to speculate that binding
of the peptide displaces and subsequently causes unfolding of the
inhibitory helix and the Ca
2+/CaM binding site, as observed in the
structure of the Ca
2+/CaM complex.
Structural Reorganization of the Catalytic and Inhibitory
Domains Induced by Ca
2+/CaM Binding
We were interested in exploring the structural consequences of
Ca
2+/CaM binding on CaMKII and determined the structure of
the CaMKIId/Ca
2+/CaM complex (Figure 2B). The structure of
the complex comprised the catalytic and the regulatory domain of
CaMKII (residues 1–333) and full length human calmodulin, and
was refined at 1.9 A ˚ resolution to an R/Rfree of 16.1 and 19.9%,
respectively (Table S1). In the complex, the regulatory region no
longer interacted with its corresponding catalytic domain
(Figure 2B). Instead, the conformation of the inhibitory region
adopted an extended conformation, in sharp contrast to its helical
secondary structure in autoinhibited CaMKII (Figure 2A). The
observed extended conformation allowed interaction between the
inhibitory region and the substrate binding site of an adjacent
catalytic domain. Most notably, T287 was aligned in a position
suitable for phosphoryl transfer (Figure 2B). Thus, the structure
effectively ‘‘captures’’ CaMKIId in the process of transphosphor-
ylation by a neighboring kinase molecule. The Ca
2+/CaM binding
region exhibits equally significant structural changes compared to
the autoinhibited kinase. Although this region displays either an
extended or partially disordered conformation in all human
autoinhibited CaMKIIs, it adopts an entirely helical secondary
structure in the Ca
2+/CaM complex (Figure 2C).
The CaMKIId/Ca
2+/CaM co-crystal structure revealed that
phosphorylation at T287 is not the only mechanism that prevents
the regulatory region from rebinding to the lower kinase lobe. In
the complex, helix aD blocked the access to the binding site for the
inhibitory helix by a significant reorientation of this helix with
respect to the autoinhibited kinase; E106 and Y107, for instance,
are displaced by more than 10 A ˚ from their position (Ca) in the
autoinhibited kinase and block the binding groove for the
inhibitory helix (Figure 2D). The movement of aD has another
important consequence which results in structural changes within
the kinase active site: E97, which is oriented away from the ATP
binding site in autoinhibited CaMKIIs, was positioned in a
conformation that enables coordination of the ATP co-factor in
the CaMKIId/Ca
2+/CaM complex. This transition has been
proposed previously based on in silico molecular dynamics
simulations using the autoinhibited CeCaMKII structure in which
the regulatory region was deleted [18]. It is well known that the
affinity of CaMKII for ATP is significantly reduced in the absence
of Ca
2+/CaM [29,31,32–34]. E97 is highly conserved in kinases
and plays a major role in recruiting ATP by forming interactions
with the sugar moiety [35]. Similar conformations involving
altered orientations of E97 that lead to kinase inactivation have
been observed in autoinhibited structures of CaMK1 [36] and
twitchin [37], suggesting that reorientation of aD is a common
regulatory mechanism in CaMKs. An animation that illustrates
the conformational changes that take place during Ca
2+/CaM-
dependent CaMKII activation has been embedded in the
enhanced version of the manuscript (Datapack S1).
Substrate Recognition of the T287 Phosphorylation Site
Transphosphorylation of T287 (T286 in CaMKIIa) by a catalytic
domain present in the same holoenzyme has been described as the
molecular switch that leads to constitutive and Ca
2+/CaM-
independent CaMKII activity [4,21,22]. The sequence flanking
T287 represents a typical CaMK consensus substrate site [38]. The
structure of the CaMKIId/Ca
2+/CaM complex revealed how the
regulatory region flanking T287 is recognized as a substrate: The
arginine residue in position 23 (R284)—a hallmark of CaMK
substrate recognition—exhibits two conformations and forms
multiple polar interactions with the aD residues E100 and E97
(Figure 3A). The conformations of residues interacting within the
substrate binding site were well defined in the electron density
(Figure 3B). The structure of this substrate complex is similar to a
CeCaMKII/peptide complex published recently [20].
We used analytical ultracentrifugation (AUC) to determine
whether the CaMKII/Ca
2+/CaM heterodimer forms in solution
and to estimate affinities for the T287-substrate interaction. In
agreement with our structural data, sedimentation velocity
experiments measured on the CaMKIId/Ca
2+/CaM complex
revealed apparent molecular weights that correspond well to the
calculated mass of the complex. The experiments also revealed the
presence of oligomers containing two or more copies of the
CaMKII/Ca
2+/CaM heterodimer (Figure 3C). We estimated
dissociation constants (KD)o f5 0mM and 120 mM, for this self-
association for the d and a isozymes, respectively (Table S2). To
further investigate whether the substrate binding pocket was
indeed the interacting interface, we performed sedimentation
velocity experiments in the presence of a substrate-competitive
peptide. When a peptide derived from CaMKIId residues 282–
310 was included, we observed only free Ca
2+/CaM and the
CaMKIId/Ca
2+/CaM heterodimer in solution, but no higher
association species. This experiment confirmed that the observed
association is mediated by the substrate binding pocket recapit-
ulating what was observed in the crystal structure of this complex.
Recognition of the CaMKIId T307 Autophosphorylation
Site
In inactive synapses, slow autophosphorylation at T306 (T307 in
CaMKIId) accumulates a CaMKII pool of subunits that cannot be
activated by Ca
2+/CaM and requires phosphatase activity for reacti-
vation [39,40]. The sequence flanking T307 represents a site that is
incompatible with CaMKII consensus substrate requirements, raising
the question as to how this regulatory phosphorylation site would be
recognized as a kinase substrate. In the CaMKIId structure, T307
was bound to the substrate binding site and oriented in an identical
fashion to that observed for T287 in the transphosphorylating
complex. The T307-containing region adopts an unusual turn
conformation not previously seen in kinase substrate complexes. This
unusual binding mode was stabilized by hydrophobic interactions of
the conserved residues I304 and L305 that bound inside a deep cavity
formedbyresidueslocatedintheP1loopandinhelixaG (Figure 4A).
This hydrophobic anchor allows recognition of this non-consensus
substrate site, thus providing insight into how T307 is recognized as a
cis-autophosphorylation site.
Binding of Ca
2+/CaM
Ca
2+/CaM has the ability to bind to a large number of distinct
proteins by adjusting the relative orientation of its EF hands
[41–43]. Residues in the interface were well-defined and the
recognition motif bound tightly within the central cavity of the
Ca
2+/CaM structure while no stable contacts were made with the
kinase domain. The Ca
2+/CaM interaction involved the CaMKII
Structural Mechanism of CaMKII Activation
PLoS Biology | www.plosbiology.org 4 July 2010 | Volume 8 | Issue 7 | e1000426Figure 2. Structure of the CaMKIId/Ca
2+/CaM complex. A) Ribbon diagram of the autoinhibited CaMKIId kinase featuring the regulatory
domain blocking the substrate binding site. Regulatory phosphorylation sites (T287, T306, T307) are marked by spheres. The region encompassing
the autoinhibitory sequence and the Ca
2+/CaM binding domain are colored green and blue respectively throughout. Helices are coloured in orange,
beta sheets in light-blue, and the ATP-competitive inhibitor is shown in stick representation. B) Ribbon diagram of the CaMKIId/Ca
2+/CaM structure
showing the regulatory region interacting with Ca
2+/CaM (colored in cyan) and a symmetry-related trans-phosphorylating ‘activating’ catalytic
domain (colored in gray). The kinase domain is shown in the same orientation as in A. For clarity, the Ca
2+/CaM associated with the trans-
phosphorylating kinase has been omitted in the figure. The phosphorylation site T287 is labeled and highlighted with a sphere. C) Structural
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human CaMKII isozymes revealed that a helical secondary
structure was induced upon Ca
2+/CaM binding for the region C-
terminal to L300. The interactions between CaMKII and Ca
2+/
CaM were largely mediated by hydrophobic contacts in the
interface of Ca
2+/CaM and the CaMKII binding helix.
Phosphorylation of T306 in CaMKIIa (T307 in other CaMKII
isoforms), located within the Ca
2+/CaM binding domain, has been
shown to inhibit Ca
2+/CaM binding [29,25]. Moreover, Ca
2+/
CaM binding to CaMKII with unphosphorylated T306 effectively
prevents phosphorylation of this residue [26]. These data are in
agreement with our co-crystal structure that showed that both
threonine residues (T306/T307) were deeply buried within the
Ca
2+/CaM complex (Figure 4B).
We used isothermal titration calorimetry (ITC) to compare the
affinities of Ca
2+/CaM to autoinhibited CaMKII catalytic
domains with those of the isolated regulatory domain and catalytic
domains of CaMKI and CaMKIV: Human CaMKII kinase
domains bound Ca
2+/CaM with affinities between 1.6 and
3.4610
6 Mol
21 (KD: 0.6–0.3 mM) (Figure 4C, Table 1). The
determined binding affinities were in agreement with affinities
determined for the full-length enzyme [33]. Ca
2+/CaM bound to
CaMKI and CaMKIV with .20-times higher affinity. Interest-
ingly, these values compared well with the affinity of the isolated
Ca
2+/CaM binding domain (CaMKIId residues 296–315)
(97.3610
6 Mol
21; KD: 10.2nM). Comparison with the affinity of
the isolated regulatory domains suggests that an energy barrier of
,2.3 kcal/mol is associated with the release of the inhibitory helix
and the Ca
2+/CaM trapping mechanism [33]. A unique feature of
the CaMKII interaction is the unfavorable (positive) binding
enthalpy. The observation that this thermodynamic fingerprint of
the binding to Ca
2+/CaM is shared by all human CaMKIIs, but
neither by CaMKI nor CaMKIV, underlines the mechanistic
differences between these classes of CaMK.
Oligomeric Assembly of CaMKII
Oligomerization into large ring-like structures is a unique
feature of CaMKIIs and the oligomeric state is crucial for rapid
autophosphorylation in trans by catalytic domains present in the
same oligomer [44]. The discrepancy between the dodecameric
(12-mer) structures determined by electron microscopy [13,14]
and the tetradecameric (14-mer) assembly revealed by the crystal
structure of the isolated oligomerization domain of the C. elegans
orthologue [15] prompted us to crystallize the oligomerizaton
domains of human CaMKII isozymes. Here we present the
oligomerization domains of the human c and d isozymes that were
refined at 2.7 and 2.8 A ˚ resolution, respectively. The quality of the
final model was substantially improved by averaging the electron
density maps using non-crystallographic symmetry. While isolated
domains of the d isozyme were tetradecameric, the CaMKIIc
oligomerization domain crystallized in its dodecameric state, thus
providing a model for the oligomerization state observed in full-
length CaMKIIs. The oligomerization domain formed a hexa-
meric structure with a diameter of 120 A ˚ and a height of 60 A ˚
surrounding a central cavity of only 17 A ˚ (Figure 5A). Thus, the
main consequence of the insertion of an additional subunit per
ring in the tetradecameric assembly is a considerable widening of
the central cavity, to about 33 A ˚.
Each oligomerization domain in the ring also contains a deep
cavity that has been suggested to represent a peptide binding site,
based on structural homology with peptide-binding domains present
in nuclear transport factors and scytalone dehydratase [15]. In
support of this hypothesis is the fact that a glycine or an acetate
molecule, respectively, originating from the crystallization solution
were partially occupying this putative binding site in the structures of
the CaMKIIc and CaMKIId oligomerization domains.
We used the structures of the dodecameric oligomerization
domain, the CaMKIId/Ca
2+/CaM complex and the structures of
the inactive catalytic domains, to construct models for the full-
length enzyme (Figure 5B). In our model of the autoinhibited
protein, catalytic domains located in both hexameric rings
associate. The pairing was chosen arbitrarily whilst based on the
orientation of the helices in the dodecameric oligomerization
domain. Binding of Ca
2+/CaM triggers unfolding of the inhibitory
helix and releases the kinase domain. This structural reorganiza-
tion allows T287 to bind to an adjacent kinase domain, leading to
autophosphorylation and restructuring of the kinase domain to
form a conformation with high affinity for ATP due to
reorientation of aD. Once T287 has been phosphorylated, the
kinase domain is released fully active and independent of Ca
2+/
CaM, and with its substrate binding site accessible.
Discussion
Four regulatory features distinguish the regulation of CaMKII
isozymes from other CaMKs. Firstly, CaMKIIs form large oligomers
bringing catalytic domains into close proximity to facilitate rapid
autoactivation. Secondly, autophosphorylation of T287 generates
Ca
2+/CaM-independent sustained activity. Thirdly, phosphorylation
of T287 increases the affinity of CaMKII for Ca
2+/CaM by more
than 10,000-fold, an effect known as CaM-trapping [45]. Fourthly,
phosphorylation of T306/T307 leads to prevention of CaMKII
activation, due to an interference with Ca
2+/CaM binding.
Comparison of the active CaMKII with its inactive autoinhibited
structures provides a structural model for the unique switch-like
mechanism of CaMKII autoactivation, as well as for its inactivation
by autophosphorylation of T307. The different molecular mecha-
nismsofCaMKIIactivationandinactivationaredepictedinFigure6,
and we discuss here the structural background of these regulatory
events in the light of the determined structures.
Autophosphorylation of T307 and its neighbor T306 prevents
binding of Ca
2+/CaM, resulting in inhibitory autophosphoryla-
tion [44]. Moreover, knock-in mice expressing mutants of
CaMKIIa incapable of phosphorylation of T306 (e.g. T306A,
corresponding to T307 in CaMKIId) identified this residue as
an important site regulating synaptic plasticity [46]. However, if
T287 is phosphorylated prior to T307, Ca
2+/CaM-independent
activity is induced, whereas prior phosphorylation of T307
prevents activation and autophosphorylation of T287. This
illustrates that the sequence of autophosphorylation events is a
critical component of CaMKII regulation [47]. In agreement
with the observation that ATP binding is impaired in
autoinhibited CaMKII, we observed only slow autophosphor-
rearrangement of the autoregulatory domain upon binding of Ca
2+/CaM. The inhibitory helix and the Ca
2+/CaM binding motif are colored in green
and blue, respectively, similar to the other subfigures D) Structural rearrangements in the catalytic domain upon binding of Ca
2+/CaM, shown by
superimposing the structures of the catalytic domain in its autoinhibited (light blue) and active (orange) state. The right panel shows an overview and
on the left a detailed view of the observed conformational changes in the lower kinase lobe is shown. For clarity, the autoinhibitory helix (aI) and coil
regions are rendered transparent and outlined in black. Residues discussed within the text are labeled.
doi:10.1371/journal.pbio.1000426.g002
Structural Mechanism of CaMKII Activation
PLoS Biology | www.plosbiology.org 6 July 2010 | Volume 8 | Issue 7 | e1000426ylation activity of CaMKIId in vitro minimizing premature
phosphorylation of T307 (unpublished data). This phosphory-
lation is stimulated by interaction with CASK [25,26]. Based on
our model of inactive CaMKIIs, it is likely that binding of
CASK leads to an allosteric rearrangement similar to the one
observed upon release of the inhibitory helix that results in
CaMKII activation and autophosphorylation of T306/T307 by
the described non-canonical binding mode of the non-consensus
substrate site at T307 in inactive CaMKIId.
A recent report showed that Angiotensin II-induced oxidation
of the methionines M281/M282 leads to sustained activity of
CaMKII in the absence of Ca
2+/CaM, inducing apoptosis in
cardiomyocytes [48]. The structure of inactive CaMKII suggests
that oxidation of M282 would lead to steric clashes with the lower
lobe, resulting in destabilization of the autoinhibited state and
Ca
2+/CaM-independent activation. In the CaMKIId/Ca
2+/CaM
complex, M282 binds into a tight hydrophobic pocket in the
substrate binding site, suggesting that oxidation of this residue also
interferes with substrate binding and autophosphorylation of T287
(see Figure 3A and 4A). Taken together, our structural data suggest
that Met oxidation interferes with both the CaMKII inactive state
and autophosphorylation of T287, thus supporting a role of M282
oxidation in CaMKII regulation [48]. The key discoveries of this
study were conformational changes that take place upon binding of
Ca
2+/CaM, resulting in activation of the kinase. These structural
rearrangements were identified by detailed comparison between the
structures of all autoinhibited CaMKIIs and the CaMKII/Ca
2+/
CaM co-crystal structure. Interestingly, CaM did not interact with
any other region of the catalytic domain of CaMKII outside the
helical recognition motif. The absence of a specific docking site for
Ca
2+/CaM on the catalytic domain proper presumably allows this
versatile modulator to interact with a large number of highly diverse
proteins by inducing structural rearrangements in its target
enzymes. Recently, the structure of a complex of Ca
2+/CaM with
DAPK1 (Death Associated Protein Kinase 1) revealed multiple
interactionsofCa
2+/CaMwith theupperandlowerkinaselobe and
binding of Ca
2+/CaM in an extended conformation [49]. In
addition, the substrate binding site in the DAPK1/Ca
2+/CaM
complex was occluded by Ca
2+/CaM, suggesting that a conforma-
tional change would need to take place to fully activate DAPK1.
CaMKIIs are only distantly related to DAPKs, and it seems that the
interaction with Ca
2+/CaM and the mechanism of activation of
these two CaMKs are fundamentally different.
All fourCaMKII isozymeswere crystallized withATP-competitive
inhibitors that are relatively non-selective. However, their binding
modes (see Figure S3) may nonetheless provide valuable chemical
starting points for structure-based design of selective and potent
inhibitors for the treatment of diseases. CaMKIIs have been
implicated in heart failure [50], arthritis [51], and certain types of
cancer [52–54]. The detailed comparison of the large body of
structural information presented here provides the first insight into
how an intact CaMKII catalytic/regulatory domain interacts with
Ca
2+/CaM. However, issues such as how catalytic domains pair
together or how activation resulting from trans-phosphorylation is
propagated in the holoenzyme would be best addressed by structures
of full length CaMKII, an effort that is ongoing in our laboratory.
Material and Methods
Protein Expression and Purification
Expression constructs comprised the following residues of
human CaMKs: CaMKId 1–333, CaMKIIa 13–301, CaMKIIb
11–302 and 358–498, CaMKIId11–335 and 334–475, CaMKIIc
5–317 and 387–527, CaMKIV 15–340, and calmodulin 1–152
Figure 3. Details of the substrate-peptide interaction. A) Binding
of the substrate sequence, including the regulatory site T287
(corresponding to T286 in the a isozyme), within the regulatory domain
to the substrate binding pocket of an interacting catalytic domain.
Substrate residues (green carbons) are labeled in bold and substrate
positions are labeled with small Arabic numbers. The side chain of R284
forms hydrogen bonds with residues located in helix aD (E97/E100).
Carbon atoms in catalytic domain residues are shown in light grey and
residues are labeled in black. B) Electron density for the substrate
peptide region. A region of the sigmaA-weighted electron density
(2mFo-DFc) is shown contoured at 1s superposed onto the final model.
C) AUC velocity experiment showing CaMKIId/Ca
2+/CaM association in
the absence (black line) and presence (red line) of the substrate-
competitive peptide encompassing the Ca
2+/CaM binding region
sequence. The assignment of the peaks to the oligomeric states (orders
of association of CaMKII/Ca
2+/CaM heterodimers) are indicated.
doi:10.1371/journal.pbio.1000426.g003
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ligation-independent cloning. Proteins were expressed in Escherichia
coli BL21(DE3)R3 as fusions to a Tobacco Etch Virus (TEV)–
cleavable N-terminal His6 affinity tag. Cells were re-suspended in
lysis buffer (50 mM HEPES pH 7.5 at 25uC, 0.3 M NaCl, 20 mM
imidazole) in the presence of a protease inhibitor mix (Complete,
EDTA-free Protease Inhibitor Cocktail, Roche Diagnostics Ltd.)
and lysed using an EmulsiFlex-C5 high pressure homogenizer
(Avestin) or, alternatively, by sonication at 4uC. The lysate was
bound to a Ni-NTA column, extensively washed (50 mM HEPES
pH 7.5, 300 mM NaCl, 20 mM imidazole) and eluted using the
same buffer containing 200 mM imidazole. Proteins were
dephosphorylated in vitro with the addition of 50 mM MnCl2
and l-phosphatase overnight at 4uC. The eluted protein was
pooled, concentrated and applied to either a Superdex 75 or 200
16/60 HiLoad gel filtration column equilibrated in 50 mM
HEPES, pH 7.5, 300 mM NaCl, 10 mM dithiothreitol (DTT).
Additional purification by ion-exchange chromatography (HiTrap
Q in 50 mM Tris pH 8.8, using 0.1 to 0.7 M NaCl gradients) was
used where purification was insufficient. Purity was monitored by
SDS-polyacrylamide gel electrophoresis and final samples were
concentrated to 10–15 mg/ml. Dephosphorylation.of CaMKIIc
was inefficient, preventing TEV-cleavage due to phosphorylation
of the TEV recognition motif. The alpha and gamma isozymes
were crystallized in fusion with the His6-TEV tag.
Crystallization and X-Ray Data Collection
Crystals were obtained by the sitting drop vapour diffusion method
at 4uC using conditions included in Table S1. Inhibitors used for co-
crystallization were added to the protein solutions prior to
crystallization at a final concentration of 1 mM. Diffraction data
were collected on beam-line X10SA at the Swiss Light Source (SLS,
Paul-Scherrer Institute, Villigen, Switzerland) from crystals flash-
frozen in liquid nitrogen.
Data Processing, Molecular Replacement and Refinement
Data were indexed and integrated using MOSFLM [55] and were
scaled using SCALA [56]. Structures were phased by molecular
replacement usingPHASER[57]withthecoordinatesofeither the C.
elegans model of inactive catalytic domain [18] or the refined
CaMKIIc, respectively, as search models. Refinement was carried
out using REFMAC5 [58] employing appropriate geometric and
non-crystallographic restraints. The models and structure factors
have been deposited with PDB accession codes listed in Table S1.
Analytical Ultracentrifugation
Sedimentation velocity experiments were carried out on an
Optima XL-I Analytical Ultracentrifuge (Beckman Instruments,
Palo Alto, CA) equipped with a Ti-50 rotor. Protein samples were
studied at a various concentrations in 10 mM HEPES pH 7.5,
containing 300 mM NaCl, 1 mM CaCl2 and 5 mM DTT at 4uC,
employing a rotor speed of 50,000 rpm. Radial absorbance scans
were collected in one-minute intervals using a double-sector cell.
300 ml aliquots were loaded into the sample channels of double-
channel 12-mm centerpieces and 310 ml of buffer into the
reference channels. Data were analyzed using SEDFIT [59,60]
to calculate c(s) distributions. SEDNTERP was used to normalize
the obtained sedimentation coefficient values to the corresponding
values in water at 20uC, s0
20,w. Translational frictional ratios
(f 0
20,w=f0) were calculated from the s20,w values, using:
(f 0
20,w=f0)~ M 1{nr0 ðÞ
.
NAs0
20,w
    
6pg0 3Mn=4pNA ðÞ
1=3
  
Figure 4. Recognition of the T307 autophosphorylation site
and Ca
2+/CaM binding. A) Substrate interaction of T307 in
autoinhibited CaMKIId. The coloring of the inhibitory helix and the
Ca
2+/CaM-binding domain is similar to Figure 2 and important residues
discussed in the text are annotated. Regulatory phosphorylation sites
are highlighted by a yellow star. B) Details of the interaction between
the Ca
2+/CaM binding site (blue helix) and Ca
2+/CaM, shown as ribbon
with semitransparent binding surfaces. Residues located in the interface
are labeled. C) Isothermal titration calorimetry (ITC) showing binding of
Ca
2+/CaM to CaMKIId (left panel) and the isolated Ca
2+/CaM binding
domain (right panel). The figure shows raw injection heats (upper
panel) and a binding isotherm of normalized integrated binding
enthalpies (lower panel). Experiments were carried out in 20 mM HEPES
pH 7.5, containing 150 mM NaCl, 5 mM DTT and 1 mM CaCl2.
doi:10.1371/journal.pbio.1000426.g004
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NA is Avogadro’s number and s0
20,w is the sedimentation coefficient
corrected to the standard conditions of density, r0, and viscosity,
g0, of water at 20.0uC, and extrapolated to infinite dilution.
Sedimentation equilibrium experiments were performed at 4uC
and at a number of protein concentrations. Dissociation constants,
Figure 5. Oligomerization domains of human CaMKIId and CaMKIIc. A) Comparison between the structures of the dodecameric (CaMKIIc)( u p p e r )
and tetradecameric (CaMKIId) (lower) arrangements. The rings are viewed looking face-on (left) and side-on (right) B) Model of the autoactivation of full-
length CaMKII. For clarity, only one CaMKII dimer is highlighted (protomers shown in green and red, respectively). The model was constructed by manual
docking of the kinase domain and the CaMKII/Ca
2+/CaM complex to the experimental structure of the dodecameric oligomerization domain.
doi:10.1371/journal.pbio.1000426.g005
Table 1. Isothermal titration calorimetry data of the interaction of Ca
2+/CaM with CaMKs.
Concentration (mM)** KB610
6 (M
21)* DH
obs (kcal/mol)* TDS (kcal/mol) DG (kcal/mol) N
CaMKIId -C a
2+/CaM 0.266/0.012 3.760.3 +5.460.05 13.8 28.4 0.933
CaMKIId - pep- Ca
2+/CaM 0.532/0.038 97.3610 +4.460.03 14.7 210.3 1.020
CaMKIIa -C a
2+/CaM 0.150/0.015 1.760.08 +12.160.13 20.2 28.0 0.863
CaMKIIb -C a
2+/CaM 0.112/0.010 2.960.2 +8.960.08 17.3 28.4 0.922
CaMKIIc -C a
2+/CaM 0.110/0.010 1.960.15 +8.660.1 16.7 28.1 0.981
CaMKI - Ca
2+/CaM 0.150/0.015 187.0684 25.860.07 4.9 210.7 1.030
CaMKI - Ca
2+/CaM 0.248/0.024 78.8621 25.160.04 5.1 210.2 0.930
CaMKIV - Ca
2+/CaM 0.156/0.088 108.0619 210.260.05 0.14 210.3 0.830
*Deviations from a non-linear least squares fit. Each data set was determined from a single titration experiment. The error was estimated from a repeated experiment
(performed for CaMKI, labeled with
1) employing re-purified CaMKI and re-purified Ca
2+/CaM. We found that binding constants had an error of approximately two-fold
with, however, similar binding enthalpy and stoichiometry.
**Values represent the concentration of the titrant (Ca
2+/CaM) and the protein (the kinase domain) in the calorimeter. For the experiment on the isolated regulatory
domain (CaMKIId pep: peptide, ARRKLGAILTTMLATRNF corresponding to Ca
2+/CaM binding domain residues 296–315 CaMKIId), the peptide was titrated into a solution
containing Ca
2+/CaM.
N: Stoichiometry of the interaction determined in the experiment.
doi:10.1371/journal.pbio.1000426.t001
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association constants, Ka,obs, according to the equation
Kd~
1
Ka,obs.e290.
d
2
,
where d is the optical pathlength and e290 the extinction coefficient
at 290 nm.
Isothermal Titration Calorimetry
ITC data were measured using a VP-ITC titration
microcalorimeter from MicroCal, LLC (Northampton, MA). For
all experiments the proteins used were dialyzed against 20 mM
HEPES pH 7.5, containing 150 mM NaCl, 5 mM DTT and
1 mM CaCl2. Data were measured at 10uC by titrating Ca
2+/CaM
into CaMKII catalytic domains or peptides into Ca
2+/CaM,
respectively. The inhibitory peptide sequence used for titrations was
ARRKLGAILTTMLATRNF, corresponding to Ca
2+/CaM bind-
ing domain residues 296–315 in CaMKIId. Each experiment
consisted of a first injection of 2 ml followed by 29 injections of 10 ml
injected during 20 s and a spacing of 280 s between injections.
Blank titrations (Ca
2+/CaM into buffer) were subtracted from the
titration data. Data were normalized and evaluated using ORIGIN
with a single binding site model. Thermodynamic parameters were
calculated using: DG=DH2TDS=2RTlnKB, where DG, DH and
DS are the changes in free energy, enthalpy and entropy of binding,
respectively.
Supporting Information
Datapack S1 Standalone iSee datapack - contains the
enhanced version of this article for use offline. This file
can be opened using free software available for download at
http://www.molsoft.com/icm_browser.html.’’
Found at: doi:10.1371/journal.pbio.1000426.s001 (ICB)
Figure S1 Sequence alignment of human CaMKIIs with
the C. elegans (Ce) orthologue. The regulatory and linker
domains are boxed. The regulatory phosphorylation sites within
the inhibitory domain are indicated by yellow stars. Catalytic/
nucleotide-binding residues are highlighted by red stars. The
secondary structure of CaMKIId is shown above the alignment
(green). However, for the regulatory region, secondary structures
are indicated for all kinases in the alignment including CaMKIId
in the absence (IId-CaM) and presence (IId+CaM) of calmodulin.
Dotted regions correspond to disordered regions that were not
modelled. The numbering above the alignment corresponds to the
sequence of CaMKIId. The start/end residues for each construct
used in crystallization are boxed in each sequence. Alignment
prepared using ALINE (Bond, C.S. and Schu ¨ttelkopf, A.W.
(2009), Acta Cryst. D65, 510–512).
Found at: doi:10.1371/journal.pbio.1000426.s002 (2.91 MB
DOC)
Figure S2 Structural overview and active site features of
autoinhibited human CaMKII isozymes. A) Superimposition
of the 4 human isozymes (CaMKIIa – yellow; CaMKIIb – grey;
CaMKIId – green; CaMKIIc – orange). Structures have been
superimposed using the lower lobe as a reference and differences in
domain orientation of the upper lobe are evident. The tip of the P-
loop is not ordered in the alpha and gamma isozymes. The main
structural elements are labelled; the inhibitory helix has been
highlighted inblue.B)Positioningofthe helixaCintheactivesite of
human CaMKII isozymes. Salt bridges between the conserved
active site lysine (K41) and the aC glutamate (E60/61) were all
between 2.7 A ˚ and 2.8 A ˚, indicating an active conformation of this
helix. The loop region linking the sheet b3 and aC as well as the aC
N terminus showed a high degree of conformational variability,
suggesting that these structural elements are quite flexible despite
the constitutively active nature of the CaMKII kinase domain. C)
CaMKII isozymes do not require activation segment phosphory-
lation for activity and the site typically phosphorylated in kinases
(211 residues from APE motif) is substituted by a highly conserved
Figure 6. Putative mechanisms of CaMKII activation and inactivation. In autoinhibited CaMKII (second from the left), the inactivating C-
terminal helix is bound to the substrate binding site (shown as a red surface). Ca
2+/CaM-independent mechanisms lead to an active state (‘‘ON’’ state;
to the top left) by methionine oxidation, or to an inactive state (‘‘OFF’’ state; bottom left) by CASK-mediated T306/T307 phosphorylation. Ca
2+/CaM-
dependent activation (to the right) is achieved through structural rearrangement of the inhibitory helix caused by Ca
2+/CaM binding and subsequent
autophosphorylation of T287. Even when calmodulin is released from the complex following a drop in the Ca
2+ level, re-binding of the inhibitory helix
is blocked (marked as a red cross) due to pT287 and a structural change in the lower kinase lobe that closes the binding site for the helix, restructures
the substrate binding site (depicted as a green surface), and aligns E97 in the active site for ATP binding. As a consequence, the active state of the
kinase is long-lasting and signaling pathways that lead to changes in gene transcription are activated.
doi:10.1371/journal.pbio.1000426.g006
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conformational stability of the activation segment is increased by a
hydrogen bond network formed by the catalytic loop R135, the
backbone oxygen of L160, G173 and P172 as well as with the side
chain oxygen of a highly conserved tyrosine (Y191) located in the
loop linking the activation segment with helix aF. In addition, the
tip of the activation segment is stabilized by a conserved cluster of
hydrophobic residues (F172, I161, V164, A170) conserved in all
CaMKII isozymes and most orthologues.
Found at: doi:10.1371/journal.pbio.1000426.s003 (2.55 MB
DOC)
Figure S3 Binding of ATP-competitive inhibitors to the
four CaMKII isozymes. The binding mode of each inhibitor is
shown in the upper panel and the inhibitor structure in the lower
panel.
Found at: doi:10.1371/journal.pbio.1000426.s004 (2.53 MB
DOC)
Table S1 Structural refinement and data collection.
Found at: doi:10.1371/journal.pbio.1000426.s005 (0.07 MB
DOC)
Table S2 Dissociation constants for the formation of dimers of
CaMK catalytic domains and of ‘‘dimers of CaMKII Ca
2+/CaM
heterodimers’’ (CaMKII-CaM)2. Protein association was monitored
using analytical ultracentrifugation sedimentation velocity experi-
ments, in 10 mM HEPES buffer containing 300 mM NaCl, 1 mM
CaCl2 and 5 mM DTT, at 4uC. Distributions of species were
analyzed using SEDFIT and dissociation constants were estimated
from the proportions between monomer/dimer and heterodimer/
heterotetramer peaks, respectively, using KD=c*(m)2/d, where c,
concentration in molar; m, proportion of monomers; d, proportion
of dimers.
Found at: doi:10.1371/journal.pbio.1000426.s006 (0.05 MB
DOC)
Text S1 Instructions for installation and use of the required web
plugin (to access the online enhanced version of this article).
Found at: doi:10.1371/journal.pbio.1000426.s007 (0.75 MB PDF)
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